Mitochondria in Huntington's disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies

Area of Science:

• Neurogenetics
• Mitochondrial Biology
• Molecular Medicine

Background:

• Huntington's disease (HD) is a genetic disorder caused by expanded CAG repeats in the huntingtin gene (HTT) on chromosome 4.
• Pathogenesis of HD involves mitochondrial dysfunction, including impaired energetics, biogenesis, quality control, trafficking, oxidative stress, and calcium dyshomeostasis.
• Current mitochondrial-targeted therapies have shown limited efficacy in HD patients.

Purpose of the Study:

• To review the role of mitochondrial dysfunction in Huntington's disease pathogenesis.
• To evaluate the potential of novel therapeutic strategies targeting mitochondrial pathways.
• To explore combination approaches involving mitochondrial restoration and genome editing for HD treatment.

Main Methods:

• Literature review of studies on Huntington's disease and mitochondrial biology.
• Analysis of evidence implicating mitochondrial defects in HD.
• Assessment of potential therapeutic interventions for mitochondrial dysfunction in HD.

Main Results:

• Mitochondrial dysfunction is a key factor in Huntington's disease progression.
• Conventional mitochondrial therapies have not been successful in treating HD.
• Restoring mitochondrial biogenesis, balancing fission/fusion, and improving trafficking are promising avenues.

Conclusions:

• Targeting mitochondrial biogenesis, fission/fusion dynamics, and trafficking holds therapeutic potential for Huntington's disease.
• Combining these mitochondrial strategies with genome editing may offer a curative approach for HD.
• Further research into mitochondrial-focused therapies is crucial for developing effective Huntington's disease treatments.